In a clinical trial involving 75 patients receiving tisagenlecleucel (CD19 CAR-T) treatment, there was a brief increase in the serum IL-6, IFN-γ, and ferritin levels during the CRS period after infusion. Here, IL6 is linked to congenital rubella syndrome.